Alnylam Pharmaceuticals
ALNY
#584
Rank
S$55.03 B
Marketcap
S$414.96
Share price
-1.32%
Change (1 day)
24.47%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): S$0.11

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is S$0.11. In 2023 the company made an earnings per share (EPS) of S-$4.46 an increase over its 2022 EPS that were of S-$11.74.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)S$0.11
2023S-$4.46-62%
2022S-$11.7429.03%
2021S-$9.10-3.36%
2020S-$9.41-8.48%
2019S-$10.287.67%
2018S-$9.5539.74%
2017S-$6.8312.94%
2016S-$6.0538.84%
2015S-$4.36-32.88%
2014S-$6.49259.44%
2013S-$1.81-31.25%
2012S-$2.63

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
S$9.30 8,077.78%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
S$2.61 2,194.62%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
S$54.48 47,811.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
S-$3.46-3,144.44%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
S-$0.92-911.11%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
S-$0.30-366.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
S$1.57 1,277.78%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
S-$1.58-1,488.89%๐Ÿ‡บ๐Ÿ‡ธ USA